U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Infiltrating bladder urothelial carcinoma

MedGen UID:
233582
•Concept ID:
C1334281
•
Neoplastic Process
Synonyms: Infiltrating Bladder Urothelial Carcinoma; infiltrating bladder urothelial carcinoma; Infiltrating Transitional Cell Carcinoma of the Urinary Bladder; infiltrating transitional cell carcinoma of the urinary bladder; Invasive Bladder Transitional Cell Carcinoma; invasive bladder transitional cell carcinoma; Invasive Bladder Urothelial Carcinoma; invasive bladder urothelial carcinoma; Invasive Transitional Cell Carcinoma of the Urinary Bladder; invasive transitional cell carcinoma of the urinary bladder
 
Monarch Initiative: MONDO:0003890

Definition

An invasive urothelial carcinoma that arises from the urinary bladder urothelium. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVInfiltrating bladder urothelial carcinoma

Professional guidelines

PubMed

Stage T1 bladder cancer: diagnostic criteria and pitfalls.
Lopez-Beltran A, Cheng L
Pathology 2021 Jan;53(1):67-85. Epub 2020 Nov 3 doi: 10.1016/j.pathol.2020.09.014. PMID: 33153725
Glandular lesions of the urinary bladder:clinical significance and differential diagnosis.
Williamson SR, Lopez-Beltran A, Montironi R, Cheng L
Histopathology 2011 May;58(6):811-34. Epub 2010 Sep 21 doi: 10.1111/j.1365-2559.2010.03651.x. PMID: 20854477
Stage pT1 bladder carcinoma: diagnostic criteria, pitfalls and prognostic significance.
Lopez-Beltran A, Cheng L
Pathology 2003 Dec;35(6):484-91. doi: 10.1080/00313020310001619127. PMID: 14660098

Recent clinical studies

Etiology

Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model.
Sato R, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Otsuka A, Miyake H
Anticancer Res 2024 Apr;44(4):1417-1423. doi: 10.21873/anticanres.16938. PMID: 38537988
Disease management in a patient diagnosed with COVID-19 disease during induction intravesical BCG therapy: A case report and review of the literature.
Ok F, Durmus E
Urologia 2023 Feb;90(1):195-197. Epub 2021 Mar 12 doi: 10.1177/03915603211001670. PMID: 33709828Free PMC Article
French AFU Cancer Committee Guidelines - Update 2022-2024: Upper urinary tract urothelial cancer (UTUC).
Neuzillet Y, Seisen T, Traxer O, Allory Y, Audenet F, Leon P, Loriot Y, Pradère B, Roumiguié M, Xylinas E, Masson-Lecomte A, Roupret M
Prog Urol 2022 Nov;32(15):1164-1194. doi: 10.1016/j.purol.2022.08.003. PMID: 36400481
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L
Nat Commun 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. PMID: 33863885Free PMC Article
Immunology of the bladder.
Graham SD Jr
Urol Clin North Am 1992 Aug;19(3):541-8. PMID: 1636238

Diagnosis

Molecular profile of bladder cancer progression to clinically aggressive subtypes.
Guo CC, Lee S, Lee JG, Chen H, Zaleski M, Choi W, McConkey DJ, Wei P, Czerniak B
Nat Rev Urol 2024 Jul;21(7):391-405. Epub 2024 Feb 6 doi: 10.1038/s41585-023-00847-7. PMID: 38321289
MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q, Zhang S, Zhang H, Sun J, Lu J, Wang G, Wang X
Int Immunopharmacol 2023 Mar;116:109783. Epub 2023 Feb 9 doi: 10.1016/j.intimp.2023.109783. PMID: 36773567
How New Developments Impact Diagnosis in Existing Renal Neoplasms.
Akgul M, Williamson SR
Surg Pathol Clin 2022 Dec;15(4):695-711. Epub 2022 Oct 13 doi: 10.1016/j.path.2022.07.005. PMID: 36344184
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L
Nat Commun 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. PMID: 33863885Free PMC Article
Immunology of the bladder.
Graham SD Jr
Urol Clin North Am 1992 Aug;19(3):541-8. PMID: 1636238

Therapy

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.
Boll LM, Perera-Bel J, Rodriguez-Vida A, Arpí O, Rovira A, Juanpere N, Vázquez Montes de Oca S, Hernández-Llodrà S, Lloreta J, Albà MM, Bellmunt J
Sci Rep 2023 Sep 15;13(1):15287. doi: 10.1038/s41598-023-42495-2. PMID: 37714872Free PMC Article
Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma.
Liang Y, Tan Y, Guan B, Guo B, Xia M, Li J, Shi Y, Yu Z, Zhang Q, Liu D, Yang X, Hao J, Gong Y, Shakeel M, Zhou L, Ci W, Li X
Theranostics 2022;12(18):7745-7759. Epub 2022 Nov 14 doi: 10.7150/thno.77281. PMID: 36451860Free PMC Article
An integrated multi-omics analysis identifies prognostic molecular subtypes of non-muscle-invasive bladder cancer.
Lindskrog SV, Prip F, Lamy P, Taber A, Groeneveld CS, Birkenkamp-Demtröder K, Jensen JB, Strandgaard T, Nordentoft I, Christensen E, Sokac M, Birkbak NJ, Maretty L, Hermann GG, Petersen AC, Weyerer V, Grimm MO, Horstmann M, Sjödahl G, Höglund M, Steiniche T, Mogensen K, de Reyniès A, Nawroth R, Jordan B, Lin X, Dragicevic D, Ward DG, Goel A, Hurst CD, Raman JD, Warrick JI, Segersten U, Sikic D, van Kessel KEM, Maurer T, Meeks JJ, DeGraff DJ, Bryan RT, Knowles MA, Simic T, Hartmann A, Zwarthoff EC, Malmström PU, Malats N, Real FX, Dyrskjøt L
Nat Commun 2021 Apr 16;12(1):2301. doi: 10.1038/s41467-021-22465-w. PMID: 33863885Free PMC Article
Id-like reaction to BCG therapy for bladder cancer.
Lowther C, Miedler JD, Cockerell CJ
Cutis 2013 Mar;91(3):145-6, 151. PMID: 23617086
Intra-arterial chemotherapy of infiltrative bladder carcinoma.
Schulman CC, Wespes E, Delcour C, Struyven J
Eur Urol 1985;11(4):220-3. doi: 10.1159/000472502. PMID: 4043159

Prognosis

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer.
Boll LM, Perera-Bel J, Rodriguez-Vida A, Arpí O, Rovira A, Juanpere N, Vázquez Montes de Oca S, Hernández-Llodrà S, Lloreta J, Albà MM, Bellmunt J
Sci Rep 2023 Sep 15;13(1):15287. doi: 10.1038/s41598-023-42495-2. PMID: 37714872Free PMC Article
Pan-cancer analysis of G6PD carcinogenesis in human tumors.
Liu B, Fu X, Du Y, Feng Z, Chen R, Liu X, Yu F, Zhou G, Ba Y
Carcinogenesis 2023 Aug 18;44(6):525-534. doi: 10.1093/carcin/bgad043. PMID: 37335542
MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q, Zhang S, Zhang H, Sun J, Lu J, Wang G, Wang X
Int Immunopharmacol 2023 Mar;116:109783. Epub 2023 Feb 9 doi: 10.1016/j.intimp.2023.109783. PMID: 36773567
Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma.
Liang Y, Tan Y, Guan B, Guo B, Xia M, Li J, Shi Y, Yu Z, Zhang Q, Liu D, Yang X, Hao J, Gong Y, Shakeel M, Zhou L, Ci W, Li X
Theranostics 2022;12(18):7745-7759. Epub 2022 Nov 14 doi: 10.7150/thno.77281. PMID: 36451860Free PMC Article
Immunology of the bladder.
Graham SD Jr
Urol Clin North Am 1992 Aug;19(3):541-8. PMID: 1636238

Clinical prediction guides

Assessment of Therapeutic Effects of Combined Treatment With Cisplatin and Anti-mouse Programmed Death (PD)-1 Antibody in a Mouse Urothelial Cancer Model.
Sato R, Watanabe K, Matsushita Y, Watanabe H, Tamura K, Motoyama D, Otsuka A, Miyake H
Anticancer Res 2024 Apr;44(4):1417-1423. doi: 10.21873/anticanres.16938. PMID: 38537988
MARCO is a potential prognostic and immunotherapy biomarker.
Dong Q, Zhang S, Zhang H, Sun J, Lu J, Wang G, Wang X
Int Immunopharmacol 2023 Mar;116:109783. Epub 2023 Feb 9 doi: 10.1016/j.intimp.2023.109783. PMID: 36773567
Single-cell atlases link macrophages and CD8(+) T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma.
Liang Y, Tan Y, Guan B, Guo B, Xia M, Li J, Shi Y, Yu Z, Zhang Q, Liu D, Yang X, Hao J, Gong Y, Shakeel M, Zhou L, Ci W, Li X
Theranostics 2022;12(18):7745-7759. Epub 2022 Nov 14 doi: 10.7150/thno.77281. PMID: 36451860Free PMC Article
Urachal yolk sac tumor penetrating the bladder as a diagnostic challenge: a case report and review of the literature.
Šámal V, Jirásek T, Paldus V, Richter I, Hes O
Diagn Pathol 2022 Jan 14;17(1):8. doi: 10.1186/s13000-022-01190-y. PMID: 35027045Free PMC Article
Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X, Wang Y, A G, Qu C, Chen J
Front Immunol 2021;12:721030. Epub 2021 Aug 31 doi: 10.3389/fimmu.2021.721030. PMID: 34531868Free PMC Article

Recent systematic reviews

Metastatic Organotropism Differential Treatment Response in Urothelial Carcinoma: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials.
Kardoust Parizi M, Matsukawa A, Bekku K, Klemm J, Alimohammadi A, Laukhtina E, Karakiewicz P, Chiujdea S, Abufaraj M, Krauter J, Shariat SF
Eur Urol Oncol 2024 Aug;7(4):663-676. Epub 2023 Nov 18 doi: 10.1016/j.euo.2023.11.001. PMID: 37980251
French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC).
Neuzillet Y, Pradère B, Xylinas E, Allory Y, Audenet F, Loriot Y, Masson-Lecomte A, Roumiguié M, Seisen T, Traxer O, Leon P, Roupret M
Prog Urol 2022 Nov;32(15):1102-1140. doi: 10.1016/j.purol.2022.08.006. PMID: 36400479
Catalog of prognostic tissue-based biomarkers in patients treated with neoadjuvant systemic therapy for urothelial carcinoma of the bladder: a systematic review.
Laukhtina E, Pradere B, Mori K, Schuettfort VM, Quhal F, Mostafaei H, Sari Motlangh R, Katayama S, Grossmann NC, Moschini M, Enikeev D, Shariat SF; European Association of Urology—Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group
Urol Oncol 2021 Mar;39(3):180-190. Epub 2021 Jan 8 doi: 10.1016/j.urolonc.2020.12.019. PMID: 33423937
Prognostic value of T1 substaging on oncological outcomes in patients with non-muscle-invasive bladder urothelial carcinoma: a systematic literature review and meta-analysis.
Kardoust Parizi M, Enikeev D, Glybochko PV, Seebacher V, Janisch F, Fajkovic H, Chłosta PL, Shariat SF
World J Urol 2020 Jun;38(6):1437-1449. Epub 2019 Sep 6 doi: 10.1007/s00345-019-02936-y. PMID: 31493109Free PMC Article

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Consumer resources

    Reviews

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...